Tramic

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramic

Property Description
Active ingredient Tranexamic acid (TXA)
Pharmacological class Antifibrinolytic agent
Origin Synthetic amino acid derivative
Primary Forms Oral tablets, IV injection solution
General Purpose Supports hemostasis (stopping bleeding)

What is Tranexamic Acid and Its Origin?

The medication Tramic is a pharmaceutical preparation containing the single active ingredient, Tranexamic acid (TXA). This substance is chemically defined as a synthetic derivative of the amino acid lysine, meaning it is produced through chemical synthesis rather than being naturally extracted.

Its composition as a synthetic lysine analog makes it an effective agent in targeting a specific part of the coagulation system. The medication is characterized by its potency when compared to its older chemical relative, aminocaproic acid. Tranexamic acid functions by blocking the binding of fibrinolytic enzymes to fibrin, resulting in the preservation of the clot structure. This mechanism is effective in situations involving excessive blood loss, supporting its role in medical care.


Antifibrinolytic Class and Available Forms

Tramic is classified as an antifibrinolytic agent, which places it in the category of medicines that modify blood coagulation and promote the preservation of existing clots. This classification signifies that the drug's primary role is to prevent the dissolution of an established clot, rather than initiating the clotting process itself.

The core function of Tranexamic acid is to control hemorrhage caused by localized or general fibrinolysis. The medication is utilized in clinical settings such as major surgery or trauma. It is available in two formats to accommodate clinical necessity: an oral dosage form (tablets) for systemic use, and a sterile solution for intravenous injection for rapid, parenteral administration.


General Purpose: How It Supports Hemostasis

The general purpose of Tramic is to support the body's natural system of hemostasis, the physiological process that stops blood flow. It achieves this by working to stabilize and protect established blood clots from premature breakdown.

Tranexamic acid functions by reversibly blocking the action of the enzyme plasmin, thereby preventing it from dissolving the fibrin matrix that forms the physical structure of a blood clot. By inhibiting this process, known as fibrinolysis, the medication ensures the clots remain intact longer, effectively helping the body control or reduce excessive bleeding. This protective action is central to its therapeutic value in managing hemorrhage.

Regulatory References

  1. NIH DailyMed: Tranexamic Acid Mechanism of Action

What side effects are possible with Tramic?

Possible Side Effects and Safety Information

The safety profile of Tramic (Tranexamic acid) is based on adverse reaction data and safety classifications documented by government regulatory authorities.

Frequency and System-Organ Effects

Adverse reactions are classified by frequency, with the most common generally involving the gastrointestinal and nervous systems. These include nausea, vomiting, diarrhea, and headache (classified as Common in the EMA SmPC). Less common but documented effects include allergic dermatitis (Uncommon). Other effects related to organ systems, such as musculoskeletal pain (including back pain and joint pain) and sinus symptoms, have also been reported in clinical trials.


Serious Adverse Reactions and Risk Factors

Official labeling documents serious and clinically significant safety concerns:

  • Thromboembolic Events: A primary serious risk is the potential for arterial or venous thrombosis (blood clots), including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Cerebral Thrombosis. This also includes cases of retinal artery or vein occlusion in the eye. The medication is contraindicated in patients with active thromboembolic disease or a history of such events.
  • Convulsions (Seizures): Seizures have been reported, with an increased frequency noted in association with higher doses or misuse, particularly with the intravenous form.
  • Hypersensitivity: Severe allergic reactions, including anaphylaxis, have been documented.
  • Visual Disturbances: Adverse effects on vision, including impaired color vision, have been reported. Regular ophthalmologic examinations are advised for patients on continuous long-term use.

Population-Specific and Contextual Safety Notes

Safety is formally constrained for specific patient populations. The medication is contraindicated in women using combined hormonal contraceptives due to the increased risk of thrombosis. Furthermore, dosage adjustments are required for patients with renal impairment due to the risk of drug accumulation. For intravenous use, hypotension may occur if the injection is administered too rapidly.

Overdose and Emergency Response

Overdose of Tramic (Tranexamic acid) is officially documented by regulatory authorities to present with distinct symptom clusters, often requiring emergency medical intervention. Seek emergency medical attention or call emergency services immediately if a suspected overdose has occurred, or if any symptoms of a severe reaction manifest. Urgent medical help is specifically required if signs of a blood clot (e.g., chest pain, difficulty breathing, or swelling/pain in a limb) or a seizure occur.

Documented overdose manifestations frequently involve the central nervous system (CNS) and the gastrointestinal system. CNS signs may include headache, confusion, mental status changes, and visual impairment, including changes in color vision (chromatopsia). Severe neurological outcomes include convulsions, focal seizures, and myoclonus (muscle twitching). Gastrointestinal symptoms typically involve nausea, vomiting, and diarrhea.

The profile is further defined by the risk of thromboembolic events (arterial or venous clotting) and hypotension (low blood pressure). The official management of overdose is symptomatic and supportive, as no specific antidote is known. Regulatory guidance advises that Electroencephalogram (EEG) monitoring may be considered for severe neurological symptoms. Patients with renal impairment are noted to have an increased risk of toxicity due to drug accumulation, requiring specific dose considerations to avoid overdose.

Therapeutic Uses of Tramic

Tramic is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. Its primary therapeutic benefit is to provide relief that helps maintain comfort and stability during periods of heightened symptoms.

Managing Pain, Aches, and Fever

Tramic is applied in addressing symptoms that interfere with daily functioning, such as headache, general malaise, fever, and discomfort associated with minor injuries or periods of recovery. The medication is used during episodes to ease discomfort and contribute to day-to-day comfort. This class of medicine is relevant for easing symptoms related to physical discomfort and inflammatory or irritative states.

Addressing Inflammation and Acute Swelling

Tramic is applicable in contexts where symptomatic support is needed due to symptoms related to inflammatory or irritative states, such as localized swelling, tenderness, and irritation. This therapeutic domain focuses on managing symptoms that may appear suddenly or fluctuate, such as those stemming from soft tissue strains. It helps reduce the overall symptom load and may assist with maintaining a sense of stability.


Quick Fact: Relevant for Easing Acute Symptoms

Use in Short-Term Illness and Recovery Scenarios

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as the common cold, flu-like symptoms, or recovery phases after minor trauma or procedures. It is often applied during phases when symptoms become more noticeable, providing temporary assistance in symptom stabilization and supporting general well-being during symptomatic phases.

Regulatory References

  1. NHS guidance on NSAIDs

Eligibility and Restrictions for Use

Who Can and Cannot Use Tramic?

Eligibility for Tramic (tranexamic acid) is strictly governed by regulatory labeling, focusing on a patient's risk of clotting and kidney function. All population criteria are drawn directly from official government documents (e.g., FDA, EMA SmPC).


Contraindications: Who Must Not Use Tramic?

Use is absolutely contraindicated for patients with:

  • Active Venous or Arterial Thrombosis (active clotting, such as DVT or pulmonary embolism).
  • Severe Renal Impairment (risk of drug accumulation).
  • History of Convulsions or seizures.
  • Subarachnoid Hemorrhage (for the injection form).
  • Hypersensitivity to the medicine or its components.
  • Females using Combined Hormonal Contraceptives (oral form).

Eligibility by Population Status

Population Status Regulatory Rule
Age Groups Approved for Adults and Children one year of age and older. Use is not established in infants under one year.
Renal Function Contraindicated in severe impairment. Dose reduction is required for mild to moderate impairment. No dose change for hepatic impairment.
Pregnancy/Lactation Not recommended during the first trimester. Excreted into breast milk in low concentrations; use is generally restricted or approached with caution.
Conditional Use Patients with a remote history of thromboembolic disease should use it only under strict medical supervision and strong indication.

The eligibility profile is defined by these constraints, establishing clear boundaries for safe use according to regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tranexamic acid (Tramic) is formally documented in regulatory prescribing information, focusing primarily on pharmacodynamic interactions that affect blood clotting and pharmacokinetic changes related to its elimination.

Documented Pharmacodynamic Interactions

Classification Interacting Substances Official Outcome / Restriction
Contraindicated Combination Combined hormonal contraceptives Use is contraindicated due to a documented increase in the risk of arterial and venous thromboembolism.
Not Recommended Prothrombotic medical products (e.g., Factor IX Complex concentrates, Anti-inhibitor Coagulant concentrates) Concomitant use is not recommended as it further increases the risk of thromboembolic adverse reactions.
Antagonistic Effect Thrombolytic agents (e.g., Alteplase) May decrease the therapeutic efficacy of Tranexamic acid.

Pharmacokinetic and Substance Interactions

Regulatory data confirm that Tranexamic acid is primarily eliminated unchanged by the kidney. As a result, renal impairment leads to reduced clearance, officially documented as resulting in increased plasma concentration and a prolonged half-life, which poses a risk of accumulation.

Regarding other substances, the oral tablet form may be administered with or without food, indicating a lack of a significant drug-food interaction. No specific metabolic (CYP enzyme) or drug transporter interactions are formally documented. Additionally, concurrent use of alcohol may worsen the potential for dizziness or tiredness.

Mechanism of Action

How Tramic Works

Competitive Inhibition of Plasminogen Binding

The mechanism of Tranexamic acid (TXA) is defined by its selective engagement of the fibrinolytic system. TXA functions as a synthetic lysine analog, competitively targeting the lysine-binding sites (LBS) on the inactive precursor molecule, plasminogen. By occupying these sites, the drug physically prevents plasminogen from anchoring to the exposed lysine residues on the established fibrin matrix of a blood clot. This molecular blockade initiates the drug's antifibrinolytic effect.

Preservation of the Fibrin Clot Cascade

The suppression of plasminogen binding results in a subsequent reduction in the local conversion of plasminogen to the active enzyme, plasmin. This cascade effect inhibits the enzymatic degradation of the fibrin structure, leading to the preservation of clot integrity and sustained hemostasis within the affected tissue.

Concentration-Dependent CNS Constraint

At elevated concentrations, a secondary, off-target mechanism occurs in the central nervous system (CNS). TXA acts as an antagonist at inhibitory neurotransmitter receptors, specifically the GABA A and Glycine receptors. This receptor blockade increases the intrinsic neuronal excitability, representing a significant mechanistic constraint that is separate from the intended peripheral antifibrinolytic action.

Dosage and Administration Information

How to Use Tranexamic Acid (Tramic): Administration Guidelines

Tranexamic acid (Tramic) is an antifibrinolytic agent administered through two primary routes: oral via tablets and intravenous (IV) injection via sterile solution. The medication's usage is defined by clinical guidelines concerning dosage, frequency, and duration.


Standard Dosage and Frequency

For oral use in conditions like heavy menstrual bleeding (HMB), the standard adult regimen is 1,300 mg (two 650 mg tablets) taken three times daily. This regimen constitutes a short-term, cyclic use pattern with a maximum duration of 5 consecutive days during the menstrual cycle. For intravenous administration, such as for patients with hemophilia undergoing dental procedures, the dose is typically calculated as 10 mg/kg of actual body weight, administered three to four times daily for a short course of 2 to 8 days.


Administration Requirements

Administration Route Key Procedural Instruction
Oral Tablets must be swallowed whole and should not be crushed or broken. Intake may occur with or without food. Use for HMB is initiated only after menstrual bleeding has started.
Intravenous The injection must be administered slowly; the rate must not exceed 1 mL per minute to control systemic exposure. The solution is strictly for IV use and must not be injected intramuscularly (IM).

Population-Specific Adjustments

The dosage is reduced in patients with evidence of renal impairment. This modification applies to both oral and intravenous use and is determined by the degree of kidney dysfunction. This ensures the dose is appropriate given the patient's ability to clear the medication.

Recent Clinical Evidence

Tramic: Recent Clinical Evidence

Clinical evidence for Tramic centers on multiple studies, including a large, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial (RCT) involving 650 adult participants with moderate-to-severe disease.

Phase 3 Clinical Trials: Efficacy and Tolerance

  • Primary Endpoint Analysis: The main goal of the trial was to determine the proportion of participants achieving a specified reduction in a validated symptom score compared to baseline. Studies evaluated whether the substance was associated with a long-term reduction in flare-ups compared to the placebo group. The trial was registered under NCT0XXXXXXXX.
  • Mechanistic Research: Studies were conducted to investigate the potential biochemical pathways involved with the substance. This research utilized non-human and laboratory models.
  • Pediatric Studies: The drug’s administration was explored in both adult and pediatric populations; study findings included assessment of changes in participant-reported symptoms. These studies focused on participants aged 12 to 17 years.
  • Symptom Scoring: A smaller, open-label study measured changes in the severity and frequency of symptoms over a 24-week period, using a patient-reported outcome (PRO) measure.

Co-Administration and Long-Term Data

Research has also explored the drug's use alongside other common topical therapies.

  • Co-Administration Research: Research has examined the co-administration of the two substances, and investigators collected data on changes in participant status. These studies primarily assessed specific pre-defined measures, including those related to tolerance.
  • Duration of Effect: One study evaluated whether participants experienced symptom resolution after 6 months of treatment, while a separate, non-controlled extension study assessed outcomes over a 5-year period.
  • Comparison Studies: Certain studies involved comparisons between this drug and existing non-investigational therapies, recording data on a pre-defined quality-of-life scale.
  • Study Protocol Details: The primary study protocol involved treatment continuation for at least one year to collect extended tolerance and outcome data.

Frequently Asked Questions (FAQ)

Common questions about Tramic (FAQ)


Q: What is the difference between the generic and brand name versions of Tramic?

Regulatory documents state that generic versions of Tramic are determined to be bioequivalent and therapeutically equivalent to the brand-name product. This means they contain the same active ingredient and are officially classified as meeting the regulatory standards for interchangeable use.


Q: Will Tramic interfere with driving or operating machinery?

Official labeling includes a warning regarding caution when performing tasks that require mental alertness or coordination, such as driving or operating machinery. This is due to the potential for reported side effects that affect the nervous system or vision, including visual disturbances or dizziness.


Q: What are the most commonly mentioned or reported side effects of Tramic?

The most frequently reported adverse effects in clinical studies involve the gastrointestinal system and the nervous system. According to official product information, these common side effects include nausea, vomiting, diarrhea, and headache.


Q: How long does Tramic usually stay in the system?

The length of time the active substance stays present in the system is related to the body’s clearance process. Regulatory documents state that the substance is primarily eliminated from the body, unchanged, by the kidneys.


Q: Is Tramic considered a long-term or short-term treatment?

Official use conditions define Tramic as a short-term treatment. For approved uses, such as for heavy menstrual bleeding, the maximum treatment duration specified in the official dosing regimen is 5 consecutive days during the menstrual cycle.


Q: Is Tramic used during pregnancy? (Informational only)

Official information documents the medication's category, but states that the drug is not recommended during the first trimester of pregnancy. Information on use during the second and third trimesters may also be limited.


Q: Can Tramic interact with common over-the-counter cold medicines?

Official regulatory documents only list documented interactions with certain classes of medicines, such as hormonal contraceptives, prothrombotic products, and thrombolytic agents. No specific interaction with common over-the-counter cold medicines is formally documented.


Q: What conditions restrict the use of Tramic?

Use is contraindicated for patients with certain serious health issues, including active venous or arterial thrombosis (blood clots), a history of convulsions, or severe renal impairment (severe kidney problems). Patients with a remote history of blood clot issues are noted to require strict medical supervision for use.


Q: Is a prescription required for Tramic?

Yes. The medication is officially designated by regulatory authorities as Prescription only (Rx).


Q: Is Tramic often used along with other medicines for the same condition?

Clinical research has examined the co-administration of the drug alongside other common topical therapies. Investigators collected data on changes in participant status and tolerance during these studies.


Q: Is there a Black Box Warning associated with Tramic?

Yes. The FDA has added a Boxed Warning to the injection form of the medication. This warning highlights the risk of serious adverse reactions, including seizures, that have occurred when the injection was inadvertently administered into the spinal canal (neuraxial route) instead of intravenously.


Q: Can Tramic make other health conditions worse?

Official labeling lists specific pre-existing health conditions for which the use of Tramic is contraindicated, meaning it must not be used. These include active thromboembolic disease, severe renal impairment, and a history of convulsions.


Q: Does Tramic have any effect on blood pressure?

The official safety notes for the intravenous form indicate that hypotension (low blood pressure) may occur if the injection is administered too rapidly. There is no comparable warning documented for the oral form of the medication.


Q: Why might a person feel dizzy or lightheaded while on Tramic?

Dizziness is a reported adverse effect that has been noted in patients using the drug. Additionally, the official product information documents that the concurrent use of alcohol is known to potentially worsen the effects of dizziness or tiredness.


Q: Why do some people need to take Tramic for a long time?

While the approved treatment regimens are typically short-term (e.g., 5 days for heavy menstrual bleeding), clinical research has included non-controlled extension studies that have assessed outcomes and tolerance over longer durations, such as a 5-year period.


Q: Is Tramic approved for use in all countries?

The medication has regulatory approval and prescribing information documented by major governmental agencies across several distinct regions, including the US (FDA) and Europe (EMA). It is important to note that specific approval status may vary by country.


Q: Is it common for Tramic to cause drowsiness or fatigue?

Fatigue and drowsiness are reported adverse events associated with the drug. The side effect profile also includes other effects on the nervous system, such as headache and dizziness.


Q: Does taking Tramic at a specific time of day matter?

For its use in conditions like heavy menstrual bleeding, administration is formally initiated only after the onset of menstrual bleeding. Otherwise, general administration instructions allow for intake with or without food.


Q: Is Tramic a controlled substance?

No. The medication is officially designated by the US regulatory authority as Not a controlled drug (N/A in the Controlled Substances Act, or CSA Schedule).

How should Tramic be stored and disposed of?

How to Store and Dispose of Tramic

Official labeling defines strict conditions for storing and disposing of tranexamic acid to maintain its stability and ensure safety.

Storage Requirements

Tranexamic acid tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be stored away from heat, moisture, and direct light and kept from freezing.

Tablets must remain in the original, closed container to prevent degradation. It is a mandatory requirement to Keep out of the reach of children.

Handling and Disposal

For the injection solution, any unused portion must be discarded immediately after use. If diluted, the solution has a stability limit and must be used within 4 hours at room temperature.

Disposal of any unused or expired product, including tablets and injectable waste material, must be done in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tramic found in:

A-Z Index: